UK markets open in 4 minutes
  • NIKKEI 225

    +240.45 (+0.91%)

    +103.97 (+0.39%)

    -0.02 (-0.04%)

    +8.60 (+0.48%)
  • DOW

    -173.77 (-0.58%)

    -244.10 (-1.82%)
  • CMC Crypto 200

    -27.27 (-7.36%)
  • ^IXIC

    +57.62 (+0.48%)
  • ^FTAS

    -25.54 (-0.70%)

Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV

Zacks Equity Research

GlaxoSmithKline plc’s GSK HIV subsidiary ViiV Healthcare announced that it has submitted a new drug application (NDA) to the FDA for its pipeline candidate fostemsavir for heavily treatment-experienced adult patients with HIV.

The candidate is being developed for use in combination with other antiretroviral agents in heavily pre-treated HIV patients, who are unable to form a suppressive regimen due to resistance, intolerance or safety considerations.

The NDA filing was based on data from the pivotal phase III BRIGHTE study. In July 2019, Glaxo presented week-96 data from the same study at the International AIDS Society Conference on HIV Science held in Mexico City.

The results showed that treatment with fostemsavir led to improvement in virologic suppression and immunologic response in such patients.

ViiV Healthcare is an HIV company, majorly owned by Glaxo and Pfizer PFE. The company plans to submit regulatory applications for fostemsavir in Europe during the coming months.

Shares of Glaxo have rallied 18.3% so far this year, outperforming the industry’s increase of 7%.

Meanwhile, Glaxo’s long-acting, injectable two-drug HIV regimen of cabotegravir plus J&J’s JNJ Edurant (rilpivirine) is under priority review in the United States with decision expected on Dec 29, 2019 from the FDA. The candidate is also under review in Europe.

Moreover, in April, Glaxo gained FDA approval for Dovato, a single tablet regimen of Tivicay (dolutegravir) + lamivudine for treatment-naïve HIV patients. Later, it was also approved in the EU in July. The new HIV medicine is off to a strong start in both the United States and the EU.

We remind investors that HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, namely Tivicay, Triumeq and Juluca in its portfolio. HIV sales totaled £3.6 billion in the first nine months of 2019. Upon potential approval, new medicines should further boost sales of the HIV franchise.

Other key players in the HIV market are Gilead GILD, Merck, AbbVie and J&J.

Zacks Rank

Glaxo currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on click here.